Advertisement
Advertisement
U.S. markets open in 6 hours 35 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
130.12-0.82 (-0.63%)
At close: 04:00PM EST
130.12 0.00 (0.00%)
After hours: 06:23PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close130.94
Open133.58
Bid0.00 x 1000
Ask0.00 x 900
Day's Range129.87 - 136.76
52 Week Range125.08 - 212.00
Volume717,739
Avg. Volume849,713
Market Cap15.562B
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-7.13
Earnings DateFeb 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est214.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ALNY

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Alnylam Pharmaceuticals, Inc.
    Analyst Report: Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
Advertisement
Advertisement